Acadia Pharmaceuticals (ACAD)

• Market cap: $2.44B
• 1 day: 1.18%
• 5 days: 0.00%
• 1 month: -12.10%
• 3 months: -21.88%
• 6 months: -1.15%
• Year to date: -21.76%
• 1 year: -12.63%
• 5 years: -69.78%
• 10 years: -57.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Employees: 654

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

138% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 29

137% more call options, than puts

Call options by funds: $18.4M | Put options by funds: $7.74M

67% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 5 (+2) [Q4]

51% more repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 72

25% more capital invested

Capital invested by funds: $2.38B [Q3] → $2.99B (+$604M) [Q4]

15% more funds holding

Funds holding: 255 [Q3] → 292 (+37) [Q4]

4.43% more ownership

Funds ownership: 93.45% [Q3] → 97.88% (+4.43%) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 37% upside
• Avg. target: $25 68% upside
• High target: $28 92% upside

6 analyst ratings

• positive: 4 67%
• neutral: 2 33%
• negative: 0 0%

UBS Ashwani Verma 25% 1-year accuracy 5 / 20 met price target	51% upside $22	Buy Maintained	28 Apr 2025
Needham Ami Fadia 22% 1-year accuracy 35 / 160 met price target	92% upside $28	Buy Reiterated	8 Apr 2025
Morgan Stanley Jeffrey Hung 15% 1-year accuracy 4 / 26 met price target	37% upside $20	Equal-Weight Assumed	7 Mar 2025
Cantor Fitzgerald Charles Duncan 31% 1-year accuracy 15 / 48 met price target	92% upside $28	Overweight Reiterated	27 Feb 2025
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target	85% upside $27	Buy Reiterated	27 Feb 2025